<DOC>
	<DOCNO>NCT02487030</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fix dose combination ( FDC ) without ribavirin ( RBV ) Egyptian adult chronic genotype 4 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir Fixed Dose Combination , With Without Ribavirin , Egyptian Adults With Chronic Genotype 4 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Willing able provide write informed consent . Chronic HCV infection ( ≥ 6 month ) document medical history liver biopsy HCV genotype 4 screen HCV treatment naive prior participation study study GSUS3340138 ( Cohorts 1 2 ) Cohort 3 : HCV treatmentexperienced ( previously receive therapy HCV infection interferon ( IFN ) contain regimen , without RBV and/or HCV NS3/NS4A protease inhibitor ( PI ) Body mass index ( BMI ) ≥ 18 kg/m^2 Screening laboratory value within define threshold Use effective protocolapproved contraception method Key History clinicallysignificant illness major medical disorder may interfere treatment , assessment compliance protocol Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Pregnant nursing female male pregnant female partner Clinicallyrelevant drug alcohol abuse within 12 month screen Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV genotype 4 ( GT-4 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>